For the quarter ending 2025-09-30, GUTS made $22,860,000 in revenue. -$45,603,000 in net income. Net profit margin of -199.49%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Research and development | 17,457,000 | 21,151,000 | 19,435,000 | 17,155,666.667 |
| Selling, general and administrative | 5,237,000 | 4,928,000 | 5,324,000 | 6,102,000 |
| Total operating expenses | 22,694,000 | 26,079,000 | 24,759,000 | 23,257,666.667 |
| Revenue | - | - | - | 26,333.333 |
| Cost of goods sold | - | - | - | 14,333.333 |
| Gross profit | - | - | - | 12,000 |
| Loss from operations | -22,694,000 | -26,079,000 | -24,759,000 | -23,245,666.667 |
| Interest income, net | 166,000 | 226,000 | 503,000 | 1,066,333.333 |
| Change in fair value of notes payable | 1,868,000 | 1,673,000 | 283,000 | -1,813,333.333 |
| Change in fair value of warrant liabilities | 21,201,000 | 348,000 | -825,000 | -5,205,000 |
| Other expense, net | -6,000 | -15,000 | -21,000 | -12,666.667 |
| Total other income (expense), net | -22,909,000 | -1,810,000 | 1,024,000 | 8,072,000 |
| Net loss and comprehensive loss | -45,603,000 | -27,889,000 | -23,735,000 | -15,173,666.667 |
| Accretion of dividends on convertible preferred stock | - | - | - | 434,250 |
| Net loss attributable to common stockholders | -45,603,000 | -27,889,000 | -23,735,000 | -15,752,666.667 |
| Earnings per share, basic, total | -0.71 | -0.57 | -0.49 | -0.38 |
| Earnings per share, diluted, total | -0.71 | -0.57 | -0.49 | -0.38 |
| Weighted average number of shares outstanding, basic, total | 64,652,953 | 49,042,926 | 48,865,468 | -1,477,474.667 |
| Weighted average number of shares outstanding, diluted, total | 64,652,953 | 49,042,926 | 48,865,468 | -1,477,474.667 |
FRACTYL HEALTH, INC. (GUTS)
FRACTYL HEALTH, INC. (GUTS)